| Title |
Development of and Access to Products for Neglected Diseases
|
|---|---|
| Published in |
PLOS ONE, May 2010
|
| DOI | 10.1371/journal.pone.0010610 |
| Pubmed ID | |
| Authors |
Joshua Cohen, Maria Staroselsky Dibner, Andrew Wilson |
| Abstract |
Prior research on neglected disease drug development suggested inadequate funding was responsible for relatively few new approvals. In response, significantly more resources have been allocated towards development of drugs targeting neglected diseases. Our objective was to reassess drug development between 1975 and 1999, evaluate progress in neglected disease drug development since 2000, and explain how increased numbers of approvals are a necessary but insufficient condition to improving access. |
Mendeley readers
The data shown below were compiled from readership statistics for 99 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Brazil | 3 | 3% |
| United Kingdom | 1 | 1% |
| Unknown | 95 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 22 | 22% |
| Researcher | 20 | 20% |
| Student > Ph. D. Student | 15 | 15% |
| Student > Bachelor | 11 | 11% |
| Professor | 6 | 6% |
| Other | 17 | 17% |
| Unknown | 8 | 8% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 19 | 19% |
| Social Sciences | 15 | 15% |
| Agricultural and Biological Sciences | 13 | 13% |
| Chemistry | 9 | 9% |
| Pharmacology, Toxicology and Pharmaceutical Science | 7 | 7% |
| Other | 24 | 24% |
| Unknown | 12 | 12% |